Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...
CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
CRISPR is in the process of a BLA for a potential breakthrough drug. The company isn't profitable and is losing its chief operating officer. CRISPR has more than $1.9 billion in cash. It opened ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
Researchers have made an important step forward toward a long-desired goal: using the gene-editing technology CRISPR to treat cancer. In a study published in Nature, scientists recruited 16 people who ...
CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
CRISPR Therapeutics AG (NASDAQ: CRSP), a gene-editing clinical-stage biotech company, saw its shares fall 19.9% in November, according to data from S&P Global Intelligence. The stock ended September ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results